Literature DB >> 12691474

Treatment of Parkinson's disease.

W R Wayne Martin1, Marguerite Wieler.   

Abstract

Parkinson's disease is a progressive neurodegenerative disorder that demands a holistic approach to treatment. Both pharmacologic and nonpharmacologic interventions play an important role in the comprehensive management of this disorder. While levodopa remains the single most effective medication for symptomatic treatment, dopamine agonists are playing an increasingly important role. Motor complications of dopaminergic therapy are a significant issue, particularly in patients with more advanced disease who have been on levodopa for several years. All therapeutic interventions must be tailored to the individual and modified as the disease progresses, with the goal of minimizing significant functional disability as much as possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691474     DOI: 10.1017/s0317167100003218

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  2 in total

1.  Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.

Authors:  Michael P Smith; Anita Fletcher-Turner; David M Yurek; Wayne A Cass
Journal:  Neurochem Res       Date:  2006-04       Impact factor: 3.996

2.  Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan.

Authors:  I-Hsun Li; Senyeong Kao; Hsiu-Feng Wu; Li-Ting Kao; Jui-Hu Shih; Hui-Han Kao; Yu-Ching Chou
Journal:  BMJ Open       Date:  2018-08-29       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.